Advertise
NEWSLETTER
IBIO-610 combined with sema...
Cognition Therapeutics wins...
United Therapeutics present...
Function, Google partner to...
Immorta Bio develops AI-des...
IBIO-610 combined with sema...
Cognition Therapeutics wins...
United Therapeutics present...
Function, Google partner to...
Immorta Bio develops AI-des...
Longevity 2020

Longevity: Start now … Introduction

Reason

Early access to the treatment of aging: distinguishing rational self-experimentation from arrant foolishness

5 investment lessons from coronavirus

Sergey Young, Founder, Longevity Vision Fund.
Thomas Weldon

Rejuvant – starting Longevity now

How can BioViva address the here and now?

Results of exogenous GDF11 supplementation in over 100 human volunteers – the view of Patient Zero

Navigating the labyrinth of dietary restriction methods

Forever Healthy – ensuring a healthy Longevity

Dr Oliver Zolman makes the case for longevity companies to adopt a check list when it comes to making anti-aging claims.

Prescribing Longevity

Philip Milgram

Prescribing Longevity Stateside

Biohack your way to Longevity

The Death of Death: the three bridges to physical immortality

What is making a transhumanist wager?

‘Longevity: Start now’ Ask Me Anything

Jim Mellon, chair and founder of Juvenescence

The Big Picture: Covid-19 and Longevity investing

Kate Batz

The view from the valley

Lorraine Morley from Allia

Accelerating agetech

Biotech AgeX Therapeutics reported financial and commercialises its stem cell lines, but continues to borrow from stakeholder Juvenescence.

The Juvenescence business model and future of anti-aging

A new analytics platform from AAA aggregates data about the latest med tech developments in the fight against Coronavirus.

Global pandemics & accelerated investment in Longevity

Reason

The crucial question in Longevity investing: is it repair?

Genome editing: opportunity & anxiety in equal measure

From science fiction to FDA submission: ectopic organoids & the commercialization of regenerative medicine

How to identify new targets and indications for aging drug development

Risk & reward: Longevity investments

5 investment lessons from coronavirus

‘Longevity investing’ Ask Me Anything

Extending healthspan with NaNot nano-extractors

Margaretta Colangelo

Interview with Margaretta Colangelo

Alex Zhavoronkov is pushing for us to examine how and when to classifying aging and how it should be implemented to overcome "inherent challenges"

Applying AI approaches to diverse aging-related problems

Margaretta Colangelo

Margaretta Colangelo in conversation with Richard Siow, John Shepherd, and Alexander Zhavoronkov

NetraMark CEO

Uncovering the heterogeneity & etiology of aging

Tina Woods

From cells to cities

AI enables a holistic approach to Superlongevity

Using AI to decode and encode the signals from the brain to the body

Leveraging AI, genomics, and biobanks to identify and target the molecular drivers of aging

‘AI & Longevity’ Ask Me Anything

Project 21 & Aubrey de Grey

The divide-and-conquer nature of rejuvenation can be an asset, not a challenge

The use of TORC1 inhibitors to improve immune function in the elderly

How do we show in humans that a drug targets aging?

Geroprotectors: time to change the way we treat older people?

Removal of senescent cells to extend healthspan & lifespan

The latest longevity science, investment, innovation and insight, delivered every morning.

Unlock Longevity Biotech Report for FREE

  • $617BN - Annual global revenue by 2045
  • $30BN+ - Invested in under 2 years
  • 3,036 - Therapeutics individually assessed